Concurrent ganirelix and follitropin beta therapy is an effective and safe regimen for ovulation induction in women with polycystic ovary syndrome.
OBJECTIVE
To evaluate controlled ovarian stimulation cycles using the GnRH antagonist ganirelix in combination with the recombinant FSH, follitropin-beta, in women with polycystic ovary syndrome (PCOS).


METHODS
Prospective, nonrandomized clinical study.


METHODS
Hospital-based infertility practice.


METHODS
Twenty women with PCOS planning to undergo ovarian stimulation.


METHODS
Fasting glucose and insulin levels were used to calculate insulin resistance ratios (FG/I). After pretreatment with oral contraceptives, serum LH levels were determined, and 250 microg ganirelix was administered on cycle day 2. Upon suppression of LH, concurrent ganirelix and follitropin-beta therapy (morning ganirelix and evening follitropin-beta) was started and continued until the day of hCG.


METHODS
Days of stimulation, dose of follitropin-beta, pregnancy, and ongoing pregnancy were compared based on FG/I ratios.


RESULTS
One dose of ganirelix effectively suppressed LH levels in all patients. All patients ovulated as documented by a rise in progesterone. Significant differences were observed between the insulin-resistant and non-insulin-resistant groups for both days of stimulation and dose of follitropin-beta. The overall clinical pregnancy rate was 44.4%, with an ongoing pregnancy rate of 27.8%.


CONCLUSIONS
In this preliminary study, we demonstrate the effectiveness of a concurrent ganirelix and follitropin-beta therapy for ovarian stimulation in women with PCOS.
Elkind-Hirsch
Karen E
KE
Woman's Health Research Institute, Woman's Hospital, Baton Rouge, Louisiana 70810, USA. keh@womans.com
Webster
Bobby W
BW
Brown
Crystal P
CP
Vernon
Michael W
MW
D001786:Blood Glucose / Q000032:analysis; D006063:Chorionic Gonadotropin / Q000008:administration & dosage; D005215:Fasting; D005260:Female; D037201:Follicle Stimulating Hormone, beta Subunit / Q000008:administration & dosage*; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors; D006727:Hormone Antagonists / Q000008:administration & dosage; D006801:Humans; D007247:Infertility, Female / Q000209:etiology / Q000628:therapy; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D007986:Luteinizing Hormone / Q000097:blood; D010062:Ovulation Induction / Q000379:methods*; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000628:therapy*; D011247:Pregnancy; D011446:Prospective Studies
D001786:Blood Glucose; D006063:Chorionic Gonadotropin; D037201:Follicle Stimulating Hormone, beta Subunit; D006727:Hormone Antagonists; D007328:Insulin; D007987:Gonadotropin-Releasing Hormone; D007986:Luteinizing Hormone; C061018:ganirelix